Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (September 2013)
19 slides from Ani Pharmaceuticals's investor presentation, Sep 20, 2013
Slide 1: A Specialty Pharmaceutical Company – Corporate Presentation September 2013
A Specialty Pharmaceutical Company NASDAQ: ANIP HIGH POTENCY DRUGS – NARCOTIC DRUGS – RX LIQUIDS AND TABLETS – CONTRACT MANUFACTURING Corporate Presentation September 2013
Slide 2: Cautionary Statement Concerning Forward-Looking Statements
2 Cautionary Statement Concerning Forward - Looking Statements This presentation and certain information incorporated herein by reference contain forward - looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
Slide 3: Mission Statement
3 3 Mission Statement ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. ANI’s mission is to utilize its manufacturing assets to develop and market niche generi
Slide 4: Company Overview – Poised for Growth
4 Company Overview – Poised for Growth ANI Today ▪ Core competencies: marketing and manufacturing ▪ Experienced management team ▪ Existing business + potential future royalty stream – For the interim six - month period ended June 30, 2013 (1 ): □ $7.5 million Rx product revenues □ $4.2 million c ont
Slide 5: Leadership – Deep Industry Experience
5 5 Leadership – Deep Industry Experience Senior Management ANI Since Previous Affiliation Arthur S. Przybyl, President and CEO 2009 Akorn (NASDAQ: AKRX) Charlotte C. Arnold, VP and CFO 2009 MVP Capital Partners Robert J. Jamnick, VP Quality and PD 2007 Solvay James G. Marken, VP Operations 2007 Sol
Slide 6: History and Highlights
6 6 History and Highlights 2004 Company founded with acquisition of over - the - counter pharmaceutical manufacturing plant in Gulfport, Mississippi 2007 ANI acquires two manufacturing plants located in Baudette , Minnesota from Solvay Pharmaceuticals 2009 New management team brought in by investors
Slide 7: Sales and Marketing Overview
7 7 Sales and Marketing Overview
Slide 8: Historical Revenue Growth
8 Historical Revenue Growth 8 $9.0M $16.5M $20.4M $11.7M $0 $5 $10 $15 $20 $25 2010 2011 2012 1H2013 $s in millions +17% Year/Year G rowth 39% 42% 43% 38% C ost of sales as a percentage of net revenues, excluding depreciation and amortization (1) Unaudited (1)
Slide 9: Current Rx Product Portfolio
9 Current Rx Product Portfolio Market Generic Products Position Share (1) Fluvoxamine Tablets #1 54% HC Enema #1 85% Opium Tincture #1 64% EE/MT Tablets #2 42% Metoclopramide Solution #2 31% 9 Branded Products Cortenema TM Reglan Tablets TM (1) Based on Company estimates, and recent IMS and NSP Audi
Slide 10: Contract Manufacturing and Royalties
10 Contract Manufacturing and Royalties 10 Current Business ▪ $4.2 million in contract manufacturing and services revenues during the six - month period ended June 30, 2013 (1) ▪ Five customers – Eleven products and fourteen SKUs Future Opportunities ▪ Three customers in development – Three products
Slide 11: Product Development / Business Development Overview
11 11 Product Development / Business Development Overview
Slide 12: Product Development Highlights
12 12 Product Development Highlights 12 p roducts in development ▪ Five filed ANDAs ▪ Seven ANDAs in progress – Development partners: Ricon and Sofgen ▪ Total combined current market: $850 million (1) Therapeutic Category Filed In Development Market Size (1) ($ in millions) Oncolytics and Narcotics
Slide 13: Business Development Highlights
13 13 Business Development Highlights Acquired undisclosed A NDA, March 2010 Acquired Reglan TM tablets, June 2011 Product development partnership with Ricon , June 2011 Acquired Bio - T - Gel™ royalty arrangement with Teva , June 2013 Product development partnership with Sofgen , August 2013
Slide 14: Manufacturing Overview
14 14 Manufacturing Overview
Slide 15: Manufacturing – Main Street Facility
15 15 Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of labora
Slide 16: Manufacturing – IDC Road Facility
16 16 Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight - ho
Slide 17: Capitalization and Shareholders
17 17 Capitalization and Shareholders
Slide 18: Capitalization and Shareholders
18 18 Capitalization and Shareholders Market capitalization (as of September 18 th , 2013) of approximately $85 million 9.5 million shares outstanding Major shareholders Ownership Officer s and Directors 3.7% Meridian Venture Partners 29.6% First Analysis Corporation 8.5% Argentum Capital Partners I
Slide 19: ANI Pharmaceuticals Poised for Growth
19 ANI Pharmaceuticals Poised for Growth
ANI Pharmaceuticals — Investor Presentation (September 2013) on 6ix